It has been reported that the prevalence of FGFR3-TACC3 fusion in bladder cancer is 2–3% [20–22] and erdafitinib was the first orally effective FGFR antagonist approved by the FDA (2019) for the treatment of the urothelial carcinoma [23]. The gene discussed is FGFR3; the disease is urinary bladder cancer.